Nanoparticle therapeutics: an emerging treatment modality for cancer

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,771 · see citing works

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · see citing works

Effect of pegylation on pharmaceuticals

Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · see citing works

Therapeutic Nanoparticles for Drug Delivery in Cancer

Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,919 · see citing works

Mechanisms of Cancer Drug Resistance

Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · see citing works

In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags

Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201 · see citing works

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159 · see citing works

Polymer conjugates as anticancer nanomedicines

Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956 · see citing works

Ligand-targeted therapeutics in anticancer therapy

Allen, T. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc903 · Cited by 1,648 · see citing works

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,129 · see citing works

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,022 · see citing works

Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein

Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931 · see citing works

Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers

Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 911 · see citing works

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855 · see citing works

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · see citing works

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

Bartlett, D. W., Su, H. C., Hildebrandt, I. J., Weber, W., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 808 · see citing works

Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability

Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742 · see citing works

Application of Nanotechnology in Cancer Therapy and Imaging

Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 696 · see citing works

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689 · see citing works

Toxicity and Tissue Distribution of Magnetic Nanoparticles in Mice

Kim, J. S., Yoon, T., Yu, K. N., Kim, B. G., Park, S. J., Kim, H. W., Lee, K. H., Park, S. B., Lee, J.-K., & Cho, M. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfj027 · Cited by 633 · see citing works

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · see citing works

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 593 · see citing works

The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery Platform

Hong, S., Leroueil, P. R., Majoros, I., Orr, B. G., Baker, J. R., & Holl, M. M. B. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.015 · Cited by 585 · see citing works

Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor

Lee, E. S., Na, K., & Bae, Y. H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.12.018 · Cited by 577 · see citing works

Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma

Hu‐Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 568 · see citing works

Functionalized micellar systems for cancer targeted drug delivery

Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557 · see citing works

Transferrin receptors in human tissues: their distribution and possible clinical relevance.

Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R.-E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 530 · see citing works

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Sparreboom, A., Scripture, C. D., Trieu, V. N., Williams, P. J., De, T., Yang, A. J., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 506 · see citing works

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei‐Tsao, D. D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizón, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · see citing works

Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability

Venturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 463 · see citing works

Polymer-drug conjugates: Recent development in clinical oncology

Li, C., & Wallace, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.009 · Cited by 437 · see citing works

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435 · see citing works

Complement activation and protein adsorption by carbon nanotubes

Salvador-Morales, C., Emmanuel Flahaut, B., Sim, E., Sloan, J., HGREEN, M., & Sim, R. B. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.02.006 · Cited by 433 · see citing works

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

Wang, Y.-S., Youngster, S. K., Grace, M. J., Bausch, J. N., Bordens, R. W., & Wyss, D. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00027-3 · Cited by 420 · see citing works

Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting

Peracchia, M. T., Fattal, E., Desmaële, D., Besnard, M., Noël, J. P., Gomis, J.-M., Appel, M., d’Angelo, J., & Couvreur, P. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00063-2 · Cited by 400 · see citing works

Pharmacological Strategies for Overcoming Multidrug Resistance

Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 395 · see citing works

Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display

Montet, X., Funovics, M. A., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388 · see citing works

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382 · see citing works

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · see citing works

Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer

Sahoo, S. K., Ma, W., & Labhasetwar, V. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327 · see citing works

Pegaspargase: a review of clinical studies

Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322 · see citing works

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer

Holmes, F. A., Jones, S. E., O’Shaughnessy, J., Vukelja, S. J., George, T. K., Savin, M., Richards, D., Glaspy, J. A., Meza, L. A., Cohen, G. I., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf130 · Cited by 291 · see citing works

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Seymour, L. W., Ferry, D. R., Anderson, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1668 · Cited by 287 · see citing works

The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)

Molineux, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452613 · Cited by 285 · see citing works

Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles

Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283 · see citing works

Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles

Vauthier, C. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.005 · Cited by 283 · see citing works

Poly (amino acid) micelle nanocarriers in preclinical and clinical studies

Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275 · see citing works

Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions

Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., & Kiessling, L. L. (2007) · ACS Chemical Biology · doi:10.1021/cb6003788 · Cited by 270 · see citing works

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed · Cited by 255 · see citing works

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253 · see citing works

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome

Suzuki, R., 知子, 滝., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagië, H., & Maruyama, K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 250 · see citing works

Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer

Modok, S., Mellor, H. R., & Callaghan, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.009 · Cited by 242 · see citing works

Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents

Zamboni, W. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1895 · Cited by 235 · see citing works

The clinical efficacy of poly(ethylene glycol)-modified proteins

Fuertges, F., & Abuchowski, A. (1990) · Journal of Controlled Release · doi:10.1016/0168-3659(90)90127-f · Cited by 227 · see citing works

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and <i>nab</i> -Paclitaxel

Gardner, E. R., Dahut, W. L., Scripture, C. D., Jones, J., Aragon-Ching, J. B., Desai, N., Hawkins, M. J., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4592 · Cited by 226 · see citing works

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models

Schluep, T., Hwang, J., Cheng, J., Heidel, J. D., Bartlett, D. W., Hollister, B. A., & Davis, M. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1566 · Cited by 222 · see citing works

Preclinical evaluation of polymer-bound doxorubicin

Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S. R., Hume, I. C., Ulbrich, K., Strohalm, J., Šubr, V., Spreafico, F., et al. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90088-9 · Cited by 187 · see citing works

Clinical Pharmacokinetics of Topotecan

Herben, V. M. M., Huinink, W. W. T. B., & Beijnen, J. H. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631020-00001 · Cited by 181 · see citing works

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Julyan, P. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00124-2 · Cited by 181 · see citing works

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.

Northfelt, D., Dezube, B. J., Thommes, J. A., Levine, R., Roenn, J. H. V., Dosik, G. M., Ríos, A., Krown, S. E., DuMond, C., & Mamelok, R. D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.653 · Cited by 170 · see citing works

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

Seymour, L. W., Ulbrich, K., Steyger, P. S., Brereton, M., Šubr, V., Strohalm, J., & Duncan, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.363 · Cited by 164 · see citing works

Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate

Singer, J. W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., & Garzone, P. D. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47932-x_6 · Cited by 156 · see citing works

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing

Bartlett, D. W., & Davis, M. E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21285 · Cited by 154 · see citing works

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study

Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., & Buchanan, G. R. (2000) · Blood · doi:10.1182/blood.v96.5.1709 · Cited by 152 · see citing works

Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells

Zhou, Y., Drummond, D. C., Zou, H., Hayes, M. E., Adams, G. P., Kirpotin, D. B., & Marks, J. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.011 · Cited by 150 · see citing works

Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice

Schluep, T., Cheng, J., Khin, K. T., & Davis, M. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0091-7 · Cited by 142 · see citing works

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane

Singer, J. W., Shaffer, S. A., Baker, B., Bernareggi, A., Stromatt, S. C., Nienstedt, D., & Besman, M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00003 · Cited by 138 · see citing works

Effect of Particle Size and Charge on the Disposition of Lipid Carriers After Intratumoral Injection into Tissue-isolated Tumors

Nomura, T., Koreeda, N., Yamashita, F., Takakura, Y., & Hashida, M. (1998) · Pharmaceutical Research · doi:10.1023/a:1011921324952 · Cited by 135 · see citing works

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Rowinsky, E. K., Rizzo, J. D., Ochoa, L., Takimoto, C. H. M., Forouzesh, B., Schwartz, G. H., Hammond, L. A., Patnaik, A., Kwiatek, J., Goetz, A. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.143 · Cited by 132 · see citing works

Pegylated liposomal doxorubicin in ovarian cancer.

Green, A. E., & Rose, P. G. (2006) · PubMed Central · Cited by 128 · see citing works

Clinical pharmacology of polyethylene glycol-L-asparaginase.

Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119 · see citing works

Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system

Chen, M. Y., Hoffer, A., Morrison, P. F., Hamilton, J. F., Hughes, J. A., Schlageter, K. S., Lee, J., Kelly, B. R., & Oldfield, E. H. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.2.0311 · Cited by 118 · see citing works

Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study

Bukowski, R. M., Ernstoff, M. S., Gore, M. E., Nemunaitis, J. J., Amato, R. J., Gupta, S. K., & Tendler, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.051 · Cited by 117 · see citing works

Designing polymer conjugates as lysosomotropic nanomedicines

Duncan, R. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350056 · Cited by 117 · see citing works

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Boddy, A. V., Plummer, E. R., Todd, R., Sludden, J., Griffin, M., Robson, L., Cassidy, J., Bissett, D., Bernareggi, A., Verrill, M. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0803 · Cited by 108 · see citing works

Phase I Trial of Poly- l -Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Homsi, J., Simon, G. R., Garrett, C. R., Springett, G. M., Conti, R. C. D., Chiappori, A., Münster, P. N., Burton, M. K., Stromatt, S. C., Allievi, C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2821 · Cited by 103 · see citing works

Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints

Pommier, Y. G. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043352777 · Cited by 102 · see citing works

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

Henderson, I. C., & Bhatia, V. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.919 · Cited by 102 · see citing works

Resolving The Nanoparticles Paradox

Donaldson, K. (2006) · Nanomedicine · doi:10.2217/17435889.1.2.229 · Cited by 94 · see citing works

Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.

Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S., & Asano, K. (1991) · PubMed · Cited by 90 · see citing works

A Nanoparticle-Based Model Delivery System To Guide the Rational Design of Gene Delivery to the Liver. 2. In Vitro and In Vivo Uptake Results

Popielarski, S. R., Hu‐Lieskovan, S., French, S. W., Triche, T. J., & Davis, M. E. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0501146 · Cited by 84 · see citing works

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

Thomson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., & Twelves, C. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690657 · Cited by 81 · see citing works

Estrogen modulation of osteoclast lysosomal enzyme secretion

Kremer, M., Judd, J., Rifkin, B. R., Auszmann, J. M., & Oursler, M. J. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240570211 · Cited by 79 · see citing works

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

Scott, L. C., Yao, J. C., Benson, A. B., Thomas, A., Falk, S. J., Mena, R. R., Picus, J., Wright, J. R., Mulcahy, M. F., Ajani, J. A., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0746-2 · Cited by 78 · see citing works

Cardiac safety of liposomal anthracyclines

Batist, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0014-4 · Cited by 62 · see citing works

SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study

Armstrong, A. C., Brewer, J., Newman, C., Alakhov, V. Y., Pietrzyński, G., Campbell, S., Corrie, P. G., Ranson, M., & Valle, J. W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4080 · Cited by 55 · see citing works

Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time

Armstrong, D. K., & Brady, M. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7140 · Cited by 52 · see citing works

Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties

Kawakami, K., Nakajima, O., Morishita, R., & Nagai, R. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.162 · Cited by 51 · see citing works

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

Posey, J. A., Saif, M. W., Carlisle, R. R., Goetz, A. D., Rizzo, J. D., Stevenson, S., Rudoltz, M. S., Kwiatek, J., Simmons, P., Rowinsky, E. K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0783 · Cited by 51 · see citing works

Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors

Nemunaitis, J. J., Cunningham, C. C., Senzer, N. N., Gray, M., Oldham, F. B., Pippen, J., Mennel, R. G., & Eisenfeld, A. J. (2005) · Cancer Investigation · doi:10.1080/07357900500359935 · Cited by 41 · see citing works

Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer

O'Brien, M. E. R. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f14a00 · Cited by 39 · see citing works

On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level

Pepin, X. J. H., Attali, L., Domrault, C., Gallet, S., Métreau, J. M., Reault, Y., Cardot, P. J. P., Imalalen, M., Dubernet, C., Soma, C. E., et al. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00362-9 · Cited by 38 · see citing works

Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response

Kraut, E. H., Fishman, M., LoRusso, P. M., Gordon, M. S., Rubin, E. H., Haas, A., Fetterly, G. J., Cullinan, P., Dul, J. L., & Steinberg, J. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2017 · Cited by 30 · see citing works

Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study

Langer, C. J., Socinski, M. A., & O'Byrne, K. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba7011 · Cited by 28 · see citing works

Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study

(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80747-x · Cited by 18 · see citing works

Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma

Delman, K. A., Brown, T. D., Thomas, M., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., & Curley, S. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4139 · Cited by 17 · see citing works

First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors

Yen, Y., Synold, T. W., Schluep, T., Hwang, J., Oliver, J., & Davis, M. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14078 · Cited by 12 · see citing works

Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors

DAUD, A. I., Garrett, C. R., Simon, G. R., Münster, P. N., Sullivan, D. M., Stromatt, S. C., Allevi, C., & Bernareggi, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2015 · Cited by 11 · see citing works

Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors.

Phan, A. T., Takimoto, C. H. M., Adinin, R., Wood, L., Xiong, H. Q., Matsuno, K., Konno, S., Fujisawa, T., & Beeram, M. (2007) · Molecular Cancer Therapeutics · Cited by 11 · see citing works

Pegylated Liposomal Doxorubicin and Immunomodulatory Drug Combinations in Multiple Myeloma: Rationale and Clinical Experience

Chanan-Khan, A. A., & Lee, K. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.018 · Cited by 11 · see citing works

Pegylated recombinant human arginase (rhArg-peg 5000mw) has in vitro and in vivo anti-proliferative potential and apoptotic activities in human hepatocellular varcinoma (HCC)

Cheng, P., Lo, T. W.-H., Leung, T.-W., Lam, A. T., & Lam, W.-M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3179 · Cited by 9 · see citing works

Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate

Todd, R., BODDY, A., Verrill, M., Sludden, J., Griffin, M., Elliott, S., Fishwick, K., Robson, L., Cassidy, J., Main, M., et al. (2001) · UCL Discovery (University College London) · doi:10.25405/ncl.34646574 · Cited by 9 · see citing works

Proteolysis of xyotax by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS

(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)81079-6 · Cited by 8 · see citing works

Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients (pts) with metastatic breast cancer (MBC)

Lee, K. S., Chung, H. C., Im, S., Park, Y. H., Kim, S. B., Kim, C. S., & Ro, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10520 · Cited by 5 · see citing works

Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma

Flaherty, L. E., Heilbrun, L. K., Marsack, C., & Vaishampayan, U. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7562 · Cited by 2 · see citing works

Exemestane: an alternative treatment option in early breast cancer

Jassem, J. (2008) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000277607.85258.de · Cited by 1 · see citing works

Metal–Organic Frameworks in Biomedicine

Horcajada, P., Gref, R., Baâti, T., Allan, P. K., Maurin, G., Couvreur, P., Férey, G., Morris, R. E., & Serre, C. (2011) · Chemical Reviews · doi:10.1021/cr200256v · Cited by 4,175 · see citing works

Strategies in the design of nanoparticles for therapeutic applications

Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651 · see citing works

Delivering nanomedicine to solid tumors

Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,196 · see citing works

Nanoparticles in Photodynamic Therapy

Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,999 · see citing works

Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery

Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,843 · see citing works

Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles

He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607 · see citing works

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,489 · see citing works

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

Hu, C. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106634108 · Cited by 2,449 · see citing works

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · see citing works

Endocytosis of nanomedicines

Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181 · see citing works

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · see citing works

Nanoscale Metal–Organic Frameworks for Biomedical Imaging and Drug Delivery

Rocca, J. D., Liu, D., & Lin, W. (2011) · Accounts of Chemical Research · doi:10.1021/ar200028a · Cited by 2,094 · see citing works

Nanoparticle PEGylation for Imaging and Therapy

Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,054 · see citing works

Applications of Carbon Nanotubes in Drug Delivery

Kaur, J., Gill, G. S., & Jeet, K. (2005) · Elsevier eBooks · doi:10.1016/b978-0-12-814031-4.00005-2 · Cited by 2,023 · see citing works

Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake

Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926 · see citing works

Cell Membrane Coating Nanotechnology

Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885 · see citing works

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez‐Herrero, E., & Fernández‐Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,888 · see citing works

Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging

Omid Veiseh, A., Gunn, J., & Zhang, M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.002 · Cited by 1,836 · see citing works

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation

Kamaly, N., Xiao, Z., Valencia, P. M., Radovic‐Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,734 · see citing works

Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications

Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010) · Nano Letters · doi:10.1021/nl102184c · Cited by 1,620 · see citing works

Polymers for Drug Delivery Systems

Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-073009-100847 · Cited by 1,608 · see citing works

Mediating Tumor Targeting Efficiency of Nanoparticles Through Design

Perrault, S. D., Walkey, C., Jennings, T. L., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,516 · see citing works

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Fang, R. H., Hu, C. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O’Connor, D. E., & Zhang, L. (2014) · Nano Letters · doi:10.1021/nl500618u · Cited by 1,509 · see citing works

Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy

Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00148 · Cited by 1,507 · see citing works

Challenges in liver cancer and possible treatment approaches

Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188314 · Cited by 1,491 · see citing works

Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery

Cheng, R., Meng, F., Deng, C., Klok, H., & Zhong, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.084 · Cited by 1,356 · see citing works

Graphene and graphene oxide as new nanocarriers for drug delivery applications

Liu, J., Cui, L., & Lošić, D. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.08.016 · Cited by 1,347 · see citing works

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324 · see citing works

Block copolymer micelles in nanomedicine applications

Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309 · see citing works

To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288 · see citing works

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,236 · see citing works

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

Lee, H., Lytton‐Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,168 · see citing works

Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions

Parodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., Brown, B. S., Khaled, S. Z., Yazdi, I. K., Enzo, M. V., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.212 · Cited by 1,174 · see citing works

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

Maeda, H., Bharate, G. Y., & Daruwalla, J. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,171 · see citing works

Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 1)

Honary, S., & Zahir, F. (2013) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v12i2.19 · Cited by 1,144 · see citing works

Spherical Nucleic Acids

Cutler, J. I., Auyeung, E., & Mirkin, C. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209351u · Cited by 1,141 · see citing works

Synthesis of Copper Peroxide Nanodots for H 2 O 2 Self-Supplying Chemodynamic Therapy

Lin, L., Huang, T., Song, J., Ou, X., Wang, Z., Deng, H., Tian, R., Liu, Y., Wang, J., Liu, Y., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03457 · Cited by 1,133 · see citing works

Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties

Sukhanova, A. V., Bozrova, S. V., Sokolov, P. M., Berestovoy, M. A., Karaulov, A. V., & Nabiev, I. R. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2457-x · Cited by 1,135 · see citing works

The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy

Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,100 · see citing works

Therapeutic Nanoparticles and Their Targeted Delivery Applications

Yetisgin, A. A., Çetinel, S., Zuvin, M., Koşar, A., & Kutlu, Ö. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,103 · see citing works

Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

Puri, A., Loomis, K. H., Smith, B. J., Lee, J. H., Yavlovich, A., Heldman, E., & Blumenthal, R. P. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,075 · see citing works

Polylactic acid (PLA) controlled delivery carriers for biomedical applications

Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050 · see citing works

The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles

Xiao, K., Li, Y., Luo, J., Lee, J. S., Xiao, W., Gonik, A. M., Agarwal, R. G., & Lam, K. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.021 · Cited by 1,039 · see citing works

Therapeutic targeting of microRNAs: current status and future challenges

Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,028 · see citing works

Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors

Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D., Roh, T., Park, J., Nilsson, J. A., Lötvall, J. O., Kim, Y., & Gho, Y. S. (2013) · ACS Nano · doi:10.1021/nn402232g · Cited by 1,024 · see citing works

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers

Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,021 · see citing works

Temperature-feedback upconversion nanocomposite for accurate photothermal therapy at facile temperature

Zhu, X., Feng, W., Chang, J., Tan, Y.-W., Li, J., Chen, M., Sun, Y., & Li, F. (2016) · Nature Communications · doi:10.1038/ncomms10437 · Cited by 1,014 · see citing works

Nanomedicine Applications of Hybrid Nanomaterials Built from Metal–Ligand Coordination Bonds: Nanoscale Metal–Organic Frameworks and Nanoscale Coordination Polymers

He, C., Liu, D., & Lin, W. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00125 · Cited by 1,006 · see citing works

Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps

Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., Schott, A. F., Kinugasa-Katayama, Y., Lee, Y., Won, N. H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1711 · Cited by 984 · see citing works

Targeting drugs to tumours using cell membrane-coated nanoparticles

Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980 · see citing works

The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic

Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 979 · see citing works

A Review of Curcumin and Its Derivatives as Anticancer Agents

Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051033 · Cited by 955 · see citing works

Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances

Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 949 · see citing works

Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy

Cheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941 · see citing works

Targeting nanoparticles to cancer

Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 928 · see citing works

Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking

Duan, X., & Li, Y. (2013) · Small · doi:10.1002/smll.201201390 · Cited by 926 · see citing works

High-Throughput Synthesis of Single-Layer MoS2 Nanosheets as a Near-Infrared Photothermal-Triggered Drug Delivery for Effective Cancer Therapy

Yin, W., Yan, L., Yu, J., Tian, G., Zhou, L., Zheng, X., Zhang, X., Yong, Y., Li, J., Gu, Z., et al. (2014) · ACS Nano · doi:10.1021/nn501647j · Cited by 920 · see citing works

Theranostic Nanoshells: From Probe Design to Imaging and Treatment of Cancer

Bardhan, R., Lal, S., Joshi, A., & Halas, N. J. (2011) · Accounts of Chemical Research · doi:10.1021/ar200023x · Cited by 918 · see citing works

Size-Controlled Synthesis of Porphyrinic Metal–Organic Framework and Functionalization for Targeted Photodynamic Therapy

Park, J., Jiang, Q., Feng, D., Mao, L., & Zhou, H.-C. “. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00007 · Cited by 916 · see citing works

Nanomaterials: Applications in Cancer Imaging and Therapy

Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 905 · see citing works

Nanomedicine in cancer therapy

Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 944 · see citing works

Development of Nanoparticles for Antimicrobial Drug Delivery

Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 890 · see citing works

Theranostic Nanomedicine

Lammers, T., Aime, S., Hennink, W. E., Storm, G., & Kiessling, F. M. (2011) · Accounts of Chemical Research · doi:10.1021/ar200019c · Cited by 873 · see citing works

Photosensitizers with Aggregation‐Induced Emission: Materials and Biomedical Applications

Hu, F., Xu, S., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201801350 · Cited by 859 · see citing works

Polymer–drug conjugate therapeutics: advances, insights and prospects

Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 867 · see citing works

Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer

Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.01.066 · Cited by 851 · see citing works

Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers

Wolinsky, J. B., Colson, Y. L., & Grinstaff, M. W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.031 · Cited by 848 · see citing works

Metal–organic frameworks as potential drug carriers

Huxford, R. C., Rocca, J. D., & Lin, W. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.12.012 · Cited by 840 · see citing works

Progress of drug-loaded polymeric micelles into clinical studies

Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837 · see citing works

Functional Gold Nanoparticles as Potent Antimicrobial Agents against Multi-Drug-Resistant Bacteria

Li, X., Robinson, S. M., Gupta, A., Saha, K., Jiang, Z., Moyano, D. F., Sahar, A. Z., Riley, M. A., & Rotello, V. M. (2014) · ACS Nano · doi:10.1021/nn5042625 · Cited by 768 · see citing works

Synthetic Nanoparticles for Vaccines and Immunotherapy

Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 770 · see citing works

Rare-earth-doped biological composites as in vivo shortwave infrared reporters

Naczynski, D. J., Tan, M. C., Zevon, M., Wall, B., Kohl, J., Kulesa, A. B., Chen, S., Roth, C. M., Riman, R. E., & Moghe, P. V. (2013) · Nature Communications · doi:10.1038/ncomms3199 · Cited by 757 · see citing works

Enzyme-responsive nanoparticles for drug release and diagnostics

de la Rica, R., Aili, D., & Stevens, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.002 · Cited by 765 · see citing works

Design considerations for tumour-targeted nanoparticles

Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754 · see citing works

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 752 · see citing works

Nanomaterials as photothermal therapeutic agents

Chen, J., Ning, C., Zhou, Z., Yu, P., Zhu, Y., Tan, G., & Mao, C. (2018) · Progress in Materials Science · doi:10.1016/j.pmatsci.2018.07.005 · Cited by 752 · see citing works

A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics

Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751 · see citing works

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744 · see citing works

DNA Origami as a Carrier for Circumvention of Drug Resistance

Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z., Zou, G., Liang, X., Yan, H., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304263n · Cited by 738 · see citing works

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · see citing works

Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy

Li, H., Du, J., Du, X., Xu, C., Sun, C.-Y., Wang, H., Cao, Z.-T., Yang, X., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 725 · see citing works

Mesoporous silica nanoparticles in medicine—Recent advances

Mamaeva, V., Sahlgren, C., & Lindén, M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 709 · see citing works

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

Choi, C. H. J., Alabi, C. A., Webster, P. C., & Davis, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699 · see citing works

Cancer nanomedicine: from targeted delivery to combination therapy

Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693 · see citing works

Targeting and delivery of platinum-based anticancer drugs

Wang, X., & Guo, Z. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35259a · Cited by 685 · see citing works

Supramolecular chemotherapy based on host–guest molecular recognition: a novel strategy in the battle against cancer with a bright future

Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 678 · see citing works

Toxicology and clinical potential of nanoparticles

Yildirimer, L., Thanh, N. T. K., Loizidou, M., & Seifalian, A. M. (2011) · Nano Today · doi:10.1016/j.nantod.2011.10.001 · Cited by 675 · see citing works

Enzyme-responsive nanomaterials for controlled drug delivery

Hu, Q., Katti, P. S., & Gu, Z. (2014) · Nanoscale · doi:10.1039/c4nr04249b · Cited by 683 · see citing works

Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application

Xia, Q., Zhang, Y., Li, Z., Hou, X., & Feng, N. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.011 · Cited by 671 · see citing works

Non-invasive delivery strategies for biologics

Anselmo, A. C., Gokarn, Y. R., & Mitragotri, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 671 · see citing works

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664 · see citing works

Investigating the optimal size of anticancer nanomedicine

Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., Yao, C., Zhou, Q., Kwon, M., Hartman, J. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411499111 · Cited by 658 · see citing works

Size Matters: Gold Nanoparticles in Targeted Cancer Drug Delivery

Dreaden, E. C., Austin, L. A., Mackey, M. A., & El‐Sayed, M. A. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.21 · Cited by 656 · see citing works

Self-catalyzed, self-limiting growth of glucose oxidase-mimicking gold nanoparticles.

Luo, W., Zhu, C., Su, S., Li, D., He, Y., Huang, Q., & Fan, C. (2010) · ACS Nano · doi:10.1021/nn102592h · Cited by 571 · see citing works

Stimuli-Responsive Therapeutic Metallodrugs

Wang, X., Wang, X., Jin, S., Nafees, M., & Guo, Z. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 651 · see citing works

DNA Origami as an In Vivo Drug Delivery Vehicle for Cancer Therapy

Zhang, Q., Jiang, Q., Li, N., Dai, L., Liu, Q. L., Song, L., Wang, J., Li, Y., Tian, J., Ding, B., et al. (2014) · ACS Nano · doi:10.1021/nn502058j · Cited by 648 · see citing works

A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma

Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645 · see citing works

Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors

Sun, H., Su, J., Meng, Q., Yin, Q., Chen, L., Gu, W., Zhang, P., Zhang, Z., Yu, H., Wang, S., et al. (2016) · Advanced Materials · doi:10.1002/adma.201602173 · Cited by 637 · see citing works

The role of micelle size in tumor accumulation, penetration, and treatment

Wang, J., Mao, W., Lock, L. L., Tang, J., Sui, M., Sun, W., Cui, H., Xu, D., & Shen, Y. (2015) · ACS Nano · doi:10.1021/acsnano.5b02017 · Cited by 635 · see citing works

Recent advances of cocktail chemotherapy by combination drug delivery systems

Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625 · see citing works

Nanoparticle therapeutics: a personal perspective

McNeil, S. E. (2009) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.6 · Cited by 231 · see citing works

Update on current and potential nanoparticle cancer therapies

Rink, J. S., Plebanek, M. P., Tripathy, S., & Thaxton, C. S. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000012 · Cited by 48 · see citing works

Introduction to cancer nanotherapeutics

Zarif, M.-E., Florea, D. A., & Grumezescu, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816506-5.00001-2

Clinical cancer nanomedicine

Wolfram, J., & Mauro Ferrari, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 438 · see citing works

Nanoparticles in Clinical Translation for Cancer Therapy

Mundekkad, D., & Cho, W. C. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 315 · see citing works